Literature DB >> 7953357

Combined resection of the pancreas and portal vein for pancreatic cancer.

S Takahashi1, Y Ogata, T Tsuzuki.   

Abstract

Between March 1976 and December 1992, 137 (57 per cent) of 239 patients with pancreatic duct cell cancer underwent resection; 79 (58 per cent) of the 137 had combined resection of the pancreas and portal vein. Sixty-three of the 79 patients underwent resection of the portal vein alone; six died (mortality rate 10 per cent). The mortality rate was the same as that in 58 patients with no resection of the portal vein. In the remaining 16 patients adjacent arteries were also resected, with seven deaths. Of patients with resection of the portal vein alone who underwent curative resection, four survived more than 5 years, accounting for nearly half of the nine 5-year survivors. Combined resection of the pancreas and portal vein is associated with both an increased resectability rate and improved long-term survival.

Entities:  

Mesh:

Year:  1994        PMID: 7953357     DOI: 10.1002/bjs.1800810837

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  30 in total

1.  Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis.

Authors:  Yanming Zhou; Zhiming Zhang; Yujian Liu; Bin Li; Donghui Xu
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

2.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

Review 3.  Oncological problems in pancreatic cancer surgery.

Authors:  Akimasa Nakao; Tsutomu Fujii; Hiroyuki Sugimoto; Naohito Kanazumi; Shuji Nomoto; Yasuhiro Kodera; Soichiro Inoue; Shin Takeda
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

4.  Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).

Authors:  J P Neoptolemos; P Baker; H Beger; K Link; P Pederzoli; C Bassi; C Dervenis; H Friess; M Büchler
Journal:  Int J Pancreatol       Date:  1997-04

5.  Pancreatic resection for pancreatic cancer.

Authors:  Jeannine Bachmann; Christoph W Michalski; Marc E Martignoni; Markus W Büchler; Helmut Friess
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

6.  Proximal migration of transanastomotic pancreatic stent following pancreaticoduodenectomy and pancreaticojejunostomy.

Authors:  B J Ammori; C M White
Journal:  Int J Pancreatol       Date:  1999-06

Review 7.  Endoscopic ultrasonography in the diagnosis and staging of pancreatic neoplasms.

Authors:  P Protiva; A V Sahai; B Agarwal
Journal:  Int J Gastrointest Cancer       Date:  2001

Review 8.  Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis.

Authors:  Markus Schäfer; Beat Müllhaupt; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

9.  Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?

Authors:  L E Harrison; D S Klimstra; M F Brennan
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

Review 10.  Pancreatic cancer: Open or minimally invasive surgery?

Authors:  Yu-Hua Zhang; Cheng-Wu Zhang; Zhi-Ming Hu; De-Fei Hong
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.